JUN 22, 2020 8:27 AM PDT

New Drug Shows Promise in Fatty Liver Disease

WRITTEN BY: Nouran Amin

A scientist leads a team to discover the first-of-its-class drug that can inhibit a key enzyme safely and effectively in people living with non-alcoholic fatty liver disease (NAFLD). The drug, an antisense inhibitor called ‘IONIS-DGAT2’, was delivered to clinical study participants via injection and was found to promote a measurable reduction in fatty liver levels.

NAFLD is a chronic metabolic disorder resulting from fat accumulating in the liver cells. It’s a common misconception that NAFLD is a result of excessive alcohol intake and could be due to a wider range of underlying health conditions. NAFLD can eventually lead to liver cirrhosis, cancer, and liver function failure.

"NAFLD wasn't even recognized as a disease three decades ago; now it is alarmingly prevalent, affecting roughly one-quarter of all Americans and emerging as one of the leading causes for liver transplant in the United States," said the study's lead author Rohit Loomba, MD, professor of medicine in the Division of Gastroenterology at UC San Diego School of Medicine and director of the UC San Diego NAFLD Research Center. "Given its relative ubiquity and its potentially calamitous consequences, safe and effective treatments are absolutely needed."

Learn more about NAFLD:

 

 

The drug is a gene silencing approach offering a new way to reverse NAFLD. It works by inhibiting an enzyme called Diacylglycerol-O-acyltransferace or DGAT2. DGAT2 is a major player in the progression of NAFLD because it catalyzes the production of fats.

"These findings showed robust reduction in liver fat by MRI without corresponding increases in blood lipids," said Loomba. "Given a significant proportion of patients achieving roughly a 30 percent reduction in MRI-PDFF, the threshold that corresponds with higher odds of histologic response when treated for a longer duration, it looks like after just 13 weeks of treatment, the drug was actually slowing the progression of NAFLD to NASH.”

Findings were published in the journal The Lancet Gastroenterology and Hepatology.

"All of this is very encouraging and argues for the next step: longer term trials to further investigate the potential of this drug in the improvement of liver histologic features associated with NASH, the progressive sub-type of NAFLD."

Source: Science Daily

About the Author
  • Nouran is a scientist, educator, and life-long learner with a passion for making science more communicable. When not busy in the lab isolating blood macrophages, she enjoys writing on various STEM topics.
You May Also Like
JUL 29, 2021
Drug Discovery & Development
A low-cost drug for the treatment of hepatitis.
JUL 29, 2021
A low-cost drug for the treatment of hepatitis.
      The viral disease, Hepatitis C, is known as a silent killer. Hepatitis C is easily spread thro ...
AUG 02, 2021
Microbiology
The Unique Microbiomes of Long-Lived People
AUG 02, 2021
The Unique Microbiomes of Long-Lived People
What's the secret of people that live a long life? The answer may be complex but for some, it could include the microbio ...
AUG 12, 2021
Drug Discovery & Development
Postpartum depression drug works through altering brain waves
AUG 12, 2021
Postpartum depression drug works through altering brain waves
     Postpartum depression is a form of depression that occurs after childbirth. This form of depres ...
AUG 18, 2021
Cannabis Sciences
Cancer Patients Use Less Cannabis than General Public
AUG 18, 2021
Cancer Patients Use Less Cannabis than General Public
Despite increasing legalization for recreational cannabis across the US, cancer patients have largely abstained from usi ...
AUG 21, 2021
Drug Discovery & Development
Schools of Fish Inspire 'Microswimmers' that Could Revolutionize Drug Delivery
AUG 21, 2021
Schools of Fish Inspire 'Microswimmers' that Could Revolutionize Drug Delivery
When 'microswimmers'- microscopic objects that can move in liquid environments- move in the same direction insid ...
SEP 14, 2021
Health & Medicine
Graphene-Oxide Based Nanotechnology and Immunology-An Exciting Partnership
SEP 14, 2021
Graphene-Oxide Based Nanotechnology and Immunology-An Exciting Partnership
As treatments and infection control practices surrounding COVID-19 continue to evolve, nanotechnological solutions are b ...
Loading Comments...